Lesniak MS - Search Results

1

CD8⁺ T-cell-Mediated Immunoediting Influences Genomic Evolution and Immune Evasion in Murine Gliomas.

Kane JR, Zhao J, Tsujiuchi T, Laffleur B, Arrieta VA, Mahajan A, Rao G, Mela A, Dmello C, Chen L, Zhang DY, González-Buendia E, Lee-Chang C, Xiao T, Rothschild G, Basu U, Horbinski C, Lesniak MS, Heimberger AB, Rabadan R, Canoll P, Sonabend AM. Kane JR, et al. Among authors: lesniak ms. Clin Cancer Res. 2020 Aug 15;26(16):4390-4401. doi: 10.1158/1078-0432.CCR-19-3104. Epub 2020 May 19. Clin Cancer Res. 2020. PMID: 32430477 Free PMC article.

2

Oligodendrogliomas: clinical significance of 1p and 19q chromosomal deletions.

Sonabend AM, Lesniak MS. Sonabend AM, et al. Among authors: lesniak ms. Expert Rev Neurother. 2005 Nov;5(6 Suppl):S25-32. doi: 10.1586/14737175.5.6.S25. Expert Rev Neurother. 2005. PMID: 16274268 Review.

3

Conditionally replicative adenoviral vectors for malignant glioma.

Sonabend AM, Ulasov IV, Lesniak MS. Sonabend AM, et al. Among authors: lesniak ms. Rev Med Virol. 2006 Mar-Apr;16(2):99-115. doi: 10.1002/rmv.490. Rev Med Virol. 2006. PMID: 16416455 Review.

4

Oncolytic adenoviral therapy for glioblastoma multiforme.

Sonabend AM, Ulasov IV, Han Y, Lesniak MS. Sonabend AM, et al. Among authors: lesniak ms. Neurosurg Focus. 2006 Apr 15;20(4):E19. Neurosurg Focus. 2006. PMID: 16709024 Review.

5

Stimulation of TLR9 with CpG ODN enhances apoptosis of glioma and prolongs the survival of mice with experimental brain tumors.

El Andaloussi A, Sonabend AM, Han Y, Lesniak MS. El Andaloussi A, et al. Among authors: lesniak ms. Glia. 2006 Nov 1;54(6):526-35. doi: 10.1002/glia.20401. Glia. 2006. PMID: 16906541

6

Enhanced transduction of malignant glioma with a double targeted Ad5/3-RGD fiber-modified adenovirus.

Tyler MA, Ulasov IV, Borovjagin A, Sonabend AM, Khramtsov A, Han Y, Dent P, Fisher PB, Curiel DT, Lesniak MS. Tyler MA, et al. Among authors: lesniak ms. Mol Cancer Ther. 2006 Sep;5(9):2408-16. doi: 10.1158/1535-7163.MCT-06-0187. Mol Cancer Ther. 2006. PMID: 16985075

7

Oncogenesis and mutagenesis of pituitary tumors.

Sonabend AM, Musleh W, Lesniak MS. Sonabend AM, et al. Among authors: lesniak ms. Expert Rev Anticancer Ther. 2006 Sep;6 Suppl 9:S3-14. doi: 10.1586/14737140.6.9s.S3. Expert Rev Anticancer Ther. 2006. PMID: 17004855 Review.

8

Role of craniotomy in the management of pituitary adenomas and sellar/parasellar tumors.

Musleh W, Sonabend AM, Lesniak MS. Musleh W, et al. Among authors: lesniak ms. Expert Rev Anticancer Ther. 2006 Sep;6 Suppl 9:S79-83. doi: 10.1586/14737140.6.9s.S79. Expert Rev Anticancer Ther. 2006. PMID: 17004861 Review.

9

Comparative evaluation of survivin, midkine and CXCR4 promoters for transcriptional targeting of glioma gene therapy.

Ulasov IV, Rivera AA, Sonabend AM, Rivera LB, Wang M, Zhu ZB, Lesniak MS. Ulasov IV, et al. Among authors: lesniak ms. Cancer Biol Ther. 2007 May;6(5):679-85. doi: 10.4161/cbt.6.5.3957. Epub 2007 Feb 3. Cancer Biol Ther. 2007. PMID: 17404502 Free article.

10

Gene therapy trials for the treatment of high-grade gliomas.

Sonabend AM, Ulasov IV, Lesniak MS. Sonabend AM, et al. Among authors: lesniak ms. Gene Ther Mol Biol. 2007;11(A):79-92. Gene Ther Mol Biol. 2007. PMID: 17625614 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

278 results

Search Page

Filters